275 related articles for article (PubMed ID: 22292442)
1. Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy.
Dickey JS; Rao VA
Curr Mol Med; 2012 Jul; 12(6):763-71. PubMed ID: 22292442
[TBL] [Abstract][Full Text] [Related]
2. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities.
Li M; Russo M; Pirozzi F; Tocchetti CG; Ghigo A
Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118493. PubMed ID: 31233802
[TBL] [Abstract][Full Text] [Related]
3. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Aspects of Anthracycline Cardiotoxicity.
Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
[TBL] [Abstract][Full Text] [Related]
6. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline cardiotoxicity: from bench to bedside.
Gianni L; Herman EH; Lipshultz SE; Minotti G; Sarvazyan N; Sawyer DB
J Clin Oncol; 2008 Aug; 26(22):3777-84. PubMed ID: 18669466
[TBL] [Abstract][Full Text] [Related]
10. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
Lenihan DJ; Stevens PL; Massey M; Plana JC; Araujo DM; Fanale MA; Fayad LE; Fisch MJ; Yeh ET
J Card Fail; 2016 Jun; 22(6):433-8. PubMed ID: 27079675
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
Geisberg CA; Sawyer DB
Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
[TBL] [Abstract][Full Text] [Related]
12. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
14. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
Robinson EL; Azodi M; Heymans S; Heggermont W
Curr Heart Fail Rep; 2020 Dec; 17(6):357-364. PubMed ID: 32964378
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
Mavinkurve-Groothuis AM; Kapusta L; Nir A; Groot-Loonen J
Pediatr Hematol Oncol; 2008 Sep; 25(7):655-64. PubMed ID: 18850478
[TBL] [Abstract][Full Text] [Related]
18. [Management of cardiovascular complications secondary to medical treatment of cancer].
Banke A; Polk A; Nielsen D; Videbæk L; Overgaard U; Fosbøl EL; Vaage-Nielsen M; Nielsen KM; Schou M
Ugeskr Laeger; 2018 Feb; 180(7):. PubMed ID: 29465031
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
20. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
